Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Cellular Origins announced an international collaboration with Thermo Fisher Scientific that will combine Thermo Fisher’s cell culture and processing technology and Cellular Origins’ CGT robotic manufacturing platform, Constellation, to deliver full,...
read more
1Elevan Biopharmaceuticals has announced its relocation from California to Fishers, Indiana, establishing its new headquarters in the Fishers Life Sciences and Innovation Park. The move represents a $7 million investment in a next-generation facility...
read more
King Faisal Specialist Hospital & Research Centre (KFSHRC) and Germfree Laboratories, LLC announced a strategic partnership to develop Saudi Arabia's first fully integrated, modular Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus.
read more
Nutriband announced that it has completed commercial manufacturing process scale-up for its lead product, Aversa™ Fentanyl, with Kindeva, a global contract development and manufacturing organization (CDMO) focused on drug-device combination products.
read more
Fareva announced the opening of a new GMP Pilot Unit at its Pau site dedicated to the production of liquid and lyophilized injectable forms.
read more
Advarra announced the launch of the Council for Responsible Use of AI in Clinical Trials. The Council, which includes leaders from across the life sciences industry, will focus on setting standards, strengthening model governance, and defining ...
read more
LOTTE BIOLOGICS announced that it has signed a contract manufacturing agreement for antibody therapeutics with Ottimo Pharma, a biopharmaceutical company developing first-in-class, one-of-a-kind PD1/VEGFR2 dual pathway antibodies to extend the lives ...
read more
The Ritedose Corporation, a pharmaceutical manufacturer specializing in Blow-Fill-Seal (BFS) technology, unveiled its new distribution and logistics facility at Performance Park during a ribbon-cutting ceremony. The grand opening event included ...
read more
Recipharm announced new product development contracts leveraging its Blow-Fill-Seal (BFS) technology.
read more
bioMérieux announced an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. This strategic ...
read more
Chrysalis, a GMP-ready space and service provider, has launched following the acquisition of facility assets from Azzur Group and a strategic ownership investment to fuel future growth and expansion.
read more
Bend Bioscience announced the opening of four new process development and manufacturing suites within its 30,000-square-foot site in Bend, Oregon. The suites will support spray drying and unit operations including granulation, encapsulation, ...
read more
Phastar announced the appointment of Billy Amzal as Head of Strategic Consulting. Amzal is a statistician, public health scientist, and entrepreneur with more than 25 years of experience across biotech and pharmaceutical industries, health agencies, ...
read more
WuXi Biologics announced the launch of WuXiHigh™2.0, a high-throughput formulation development platform designed for high concentration biologics. The platform enables protein concentrations of up to 230 mg/mL and achieves viscosity reduction by up ...
read more
AbbVie and Capstan Therapeutics announced a definitive agreement under which AbbVie will acquire Capstan, including CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate, currently in Phase 1, in development for the ...
read more